|  | Study A (Calibration) (N=41) | Study B (Validation) (N=22) | Overall (N=63) |
| --- | --- | --- | --- |
| **Vaccine type** |  |  |  |
| BNT162b2 | 33 (80.5%) | 11 (50.0%) | 44 (69.8%) |
| ChAdOx1 | 8 (19.5%) | 11 (50.0%) | 19 (30.2%) |
| **Time since first dose (days)** |  |  |  |
| <28 days | 26 (63.4%) | 9 (40.9%) | 35 (55.6%) |
| 28+ days | 15 (36.6%) | 13 (59.1%) | 28 (44.4%) |
| **Age (yrs)** |  |  |  |
| <30 years | 3 (7.3%) | 4 (18.2%) | 7 (11.1%) |
| 30–39 years | 15 (36.6%) | 6 (27.3%) | 21 (33.3%) |
| 40–49 years | 8 (19.5%) | 3 (13.6%) | 11 (17.5%) |
| 50–59 years | 13 (31.7%) | 6 (27.3%) | 19 (30.2%) |
| 60+ years | 2 (4.9%) | 3 (13.6%) | 5 (7.9%) |